The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. This phase II trial tests how well pertuzumab, trastuzumab, hyaluronidase-zzxf ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

Monoclonal antibodies (mAbs) targeting receptors of the Epidermal Growth Factor Receptor (EGFR) family, including anti-EGFR cetuximab and panitumumab and anti-ErbB2 trastuzumab and pertuzumab, are ...

Giredestrant is a new type of hormone treatment. It blocks the hormone oestrogen. Pertuzumab and trastuzumab are usual treatments for breast cancer that has tested positive for HER2. The combination ...

And, in fact, this study showed that the additional palbociclib to this kind of treatment was able to significantly prolong ...

In the article that accompanies this editorial, 16 the authors report clinical outcomes from the Japanese phase III JBCRG-M06/EMERALD trial, which compared first-line eribulin plus dual human ...

Copyright: © 2009 Elsevier Ltd. Published by Elsevier Ltd. The approval of trastuzumab for use in metastatic breast cancer marked a breakthrough in the understanding ...

It is recommended that women with early HER2+ breast cancer receive neoadjuvant subtype-specific systemic therapy, followed by surgery. 3 Paclitaxel plus trastuzumab, docetaxel/carboplatin ...